Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.53 is 77% below its 5-year average of -0.30, near the low end of its 5-year range (-2.86–459.88).
As of the fiscal period ended Tuesday, June 30, 2026. 31.50% below its 12-month average of -0.40.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.53.
DEBT TO EQUITY RATIO
-0.53
DEBT TO EQUITY RATIO AVG TTM
-0.40
DEBT TO EQUITY RATIO AVG 3Y
-0.63
DEBT TO EQUITY RATIO AVG 5Y
-0.30
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-31.50%
CURRENT VS 3Y AVG
+16.03%
CURRENT VS 5Y AVG
-77.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 508 covered companies
CURRENT VS SECTOR MEDIAN
-479.90%
vs the sector median at left
Foghorn Therapeutics Inc.
Market Cap
$108.33M
Debt to Equity Ratio
-0.53
TTM Avg
-0.40
3Y Avg
-0.63
5Y Avg
-0.30
Market Cap
$109.91M
Debt to Equity Ratio
3.72
TTM Avg
2.72
3Y Avg
1.72
5Y Avg
1.15
Market Cap
$107.45M
Debt to Equity Ratio
0.18
TTM Avg
0.22
3Y Avg
0.23
5Y Avg
0.18
Market Cap
$106.83M
Debt to Equity Ratio
0.27
TTM Avg
0.66
3Y Avg
0.63
5Y Avg
0.55
Market Cap
$109.64M
Debt to Equity Ratio
0.01
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$105.15M
Debt to Equity Ratio
1.15
TTM Avg
0.59
3Y Avg
0.44
5Y Avg
0.41
Market Cap
$112.13M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $108.33M | -0.53 | -0.40 | -0.63 | -0.30 |
| BGM Group Ltd. (BGM)vs › | $112.03M | 0.00 | 0.00 | 0.01 | 0.08 |
| Apyx Medical Corporation (APYX)vs › | $109.91M | 3.72 | 2.72 | 1.72 | 1.15 |
| Immunic, Inc. (IMUX)vs › | $108.43M | 0.00 | 0.05 | 0.03 | 0.02 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.45M | 0.18 | 0.22 | 0.23 | 0.18 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.83M | 0.27 | 0.66 | 0.63 | 0.55 |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.64M | 0.01 | 0.00 | 0.00 | 0.00 |
| Definitive Healthcare Corp. (DH)vs › | $105.15M | 1.15 | 0.59 | 0.44 | 0.41 |
| Coya Therapeutics, Inc. (COYA)vs › | $112.13M | 0.00 | 0.00 | 0.00 | 0.00 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $105.61M | 0.04 | 0.01 | 0.26 | 0.35 |
Debt/Equity
-0.53
Current Ratio
3.36
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.53 |
| 2026-03-31 | -0.55 |
| 2025-12-31 | -0.38 |
| 2025-09-30 | -0.25 |
| 2025-06-30 | -0.31 |
| 2025-03-31 | -0.57 |
| 2024-12-31 | -0.82 |
| 2024-09-30 | -1.38 |
| 2024-06-30 | -2.86 |
| 2024-03-31 | -0.44 |
| 2023-12-31 | -0.58 |
| 2023-09-30 | -0.82 |
| 2023-06-30 | -0.97 |
| 2023-03-31 | -2.03 |
| 2022-12-31 | 459.88 |
| 2022-09-30 | 2.19 |
| 2022-06-30 | 1.15 |
| 2022-03-31 | 0.78 |
| 2021-12-31 | 0.60 |
| 2021-09-30 | 0.99 |
| 2021-06-30 | 0.78 |
| 2021-03-31 | 0.66 |
| 2020-12-31 | 0.56 |
| 2020-09-30 | -0.53 |
| 2020-06-30 | 3.63 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | -0.19 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
